source
- Boehringer Ingelheim boosts Variant Bio partnership with $250 million for cardiovascular researchBoehringer Ingelheim announced an expansion of its collaboration with Variant Bio. The partnership will now include cardiovascular disease research, broadening its original scope. The deal value…
- Human‑centric testing methods promise safer, cheaper drug development but repeatability remains a key obstacleRegulators such as the FDA, EMA and ICH are urging drug developers to replace animal safety studies with New Approach Methodologies that use human‑relevant models. Early research shows these models…